With a market cap of $116.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company focused on ...

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth-quarter 2025 ...

This was the stock's sixth consecutive day of losses.

If you are wondering whether Vertex Pharmaceuticals' current share price reflects its long term potential, a useful starting ...

Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...

There is no sugarcoating it: Vertex Pharmaceuticals (NASDAQ: VRTX) has faced significant issues this year that have sunk its stock price. The company's shares are down 2% year-to-date, while the S&P ...

Vertex Pharmaceuticals dominates the cystic fibrosis treatment market and recently has expanded into other therapeutic areas. The biotech predicts full-year 2025 revenue of as much as $12 billion.

The firm said its upgrade reflects increased revenue forecasts for Vertex’s renal programs and higher valuation multiples, lifting its price target to $572. Bernstein sees a high probability that ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $496.45, a high estimate of $564.00, and a low estimate of $414.00. Witnessing a positive shift, the ...

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...